Production (Stage)
Lexeo Therapeutics, Inc.
LXEO
$3.88
$0.6118.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.61% | -82.73% | -46.65% | -58.00% | -16.21% |
| Total Depreciation and Amortization | 5.25% | 6.33% | 10.65% | 11.21% | 6.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.12% | 228.06% | 231.00% | 193.70% | 487.15% |
| Change in Net Operating Assets | 67.91% | -376.00% | 62.14% | -93.65% | 814.44% |
| Cash from Operations | -46.07% | -102.60% | -27.65% | -52.76% | 19.09% |
| Capital Expenditure | -- | 100.00% | -2,666.67% | -446.15% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 195,100.00% | -- | 100.00% | -- | -- |
| Cash from Investing | 8,182.90% | -128,095.89% | -56.60% | -458.97% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -45.87% | -10.48% | -3.74% | 28.16% | 0.91% |
| Issuance of Common Stock | -99.81% | -93.70% | 30.00% | 4,100.00% | 739,591.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -8,284.00% | -- | -- | -- |
| Cash from Financing | -99.99% | -100.10% | -101.84% | 409.57% | 90,563.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.30% | -241.84% | -78.01% | -50.69% | 498.41% |